The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia

• Peter M. Alexander,

  Affiliation Internal Medicine, Section on Hematology and Oncology, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America

  ⨯
• David L. Caudell,

  Affiliation Pathology-Comparative Medicine, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America

  ⨯
• Gregory L. Kucera,

  Affiliations Internal Medicine, Section on Hematology and Oncology, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America, Cancer Biology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States of America

  ⨯
• Kristin M. Pladna,

  Affiliation Internal Medicine, Section on Hematology and Oncology, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America

  ⨯
• Timothy S. Pardee

  * E-mail: tspardee@wakehealth.edu

  Affiliations Internal Medicine, Section on Hematology and Oncology, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States of America, Cancer Biology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States of America

  http://orcid.org/0000-0002-1186-6948

  ⨯